OR WAIT 15 SECS
PCI Pharma has announced the creation of a new clinical center of excellence in Western Europe at its site in Berlin, Germany.
Pharmaceutical and biopharmaceutical global outsourcing solutions provider, PCI Pharma, has announced the creation of a new clinical center of excellence (COE) in Western Europe at its site in Berlin, Germany.
According to a July 28, 2020 press release, the company’s investment in the COE forms part of its global strategy to expand its clinical supply chain network into continental Europe, which will complement offerings available in the United Kingdom and Ireland. The Berlin COE is expected to be completed in January 2021.
“With this expansion, our Berlin Clinical Center of Excellence will address the needs of European and global clients,” said Brian Keesee, vice president and general manager, Global Clinical Operations and Supply, PCI Pharma Services, in the press release. “Berlin is an excellent logistical hub that will serve as a proactive solution to Brexit, ensuring there are no gaps in the supply chain and our clients conducting clinical trials in all parts of Europe continue to be served.”
At the new COE, there will be 17,000 ft2 of space dedicated to primary and secondary packaging, storage of pharmaceutical and biopharmaceutical therapies at all temperature ranges, and distribution. The capacity is ideally positioned to serve the clinical trials ecosystem in the European Union.
“Our strategy has always been to increase the capacity and capabilities of our clinical trial services network, and with the acquisition of Bellwyck Pharma Services earlier this year, we are taking the next step to enhance our capabilities at our new Berlin facility to support the growing clinical trial market in Europe and beyond,” added Salim Haffar, CEO, PCI Pharma Services, in the press release. “This investment will provide clients with global clinical trial solutions for their life-changing medicines, ensuring continuity of patient supply to match growing market demands.”